Trial Profile
A randomized, double-blind, parallel-group trial comparing bicalutamide (Casodex) 150mg once daily with placebo in patients with non-metastatic prostate cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAPRI
- Sponsors AstraZeneca
- 07 Jan 2009 Acronym identified as CAPRI, reported by Clinicaltrials.gov.
- 07 Jan 2009 Actual end date reported as October 2008 by Clinicaltrials.gov.
- 07 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.